| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PLoSO...865801Z |
| P356 | DOI | 10.1371/JOURNAL.PONE.0065801 |
| P932 | PMC publication ID | 3675064 |
| P698 | PubMed publication ID | 23762429 |
| P5875 | ResearchGate publication ID | 237200696 |
| P50 | author | V. Wee Yong | Q56101901 |
| Grant McFadden | Q88652661 | ||
| P2093 | author name string | Peter A Forsyth | |
| Franz J Zemp | |||
| Brienne A McKenzie | |||
| Lori Maxwell | |||
| Xueqing Lun | |||
| Karlyne M Reilly | |||
| P2860 | cites work | Innate cellular response to virus particle entry requires IRF3 but not virus replication | Q24607212 |
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates | Q27007519 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects | Q28511432 | ||
| Malignant gliomas in adults | Q29615708 | ||
| Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines | Q29615823 | ||
| Defective translational control facilitates vesicular stomatitis virus oncolysis | Q42831942 | ||
| Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models | Q44669457 | ||
| Intraventricular injection of myxoma virus results in transient expression of viral protein in mouse brain ependymal and subventricular cells. | Q45372866 | ||
| Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier | Q45560504 | ||
| Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens | Q48559424 | ||
| Prognosis of gliomas in the 1970s and today | Q48921212 | ||
| Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. | Q55463256 | ||
| Collagens, integrins and the mesenchymal drift in glioblastomas: A comparison of biopsy specimens, spheroid and early monolayer cultures | Q55481758 | ||
| Induction of experimental allergic encephalomyelitis in genetically resistant strains of mice | Q59084927 | ||
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion | Q29617359 | ||
| Behavior of a cloned murine interferon alpha/beta receptor expressed in homospecific or heterospecific background. | Q30839933 | ||
| Role for gamma interferon in control of herpes simplex virus type 1 reactivation. | Q33645342 | ||
| Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production | Q33667768 | ||
| Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM | Q33712977 | ||
| Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus | Q33908950 | ||
| Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. | Q34032640 | ||
| The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study | Q34124333 | ||
| Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 | ||
| Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. | Q34343768 | ||
| Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human | Q34503355 | ||
| Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies | Q35021348 | ||
| Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas | Q35216380 | ||
| Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. | Q35234447 | ||
| Oncolytic virotherapy for pancreatic cancer | Q35590996 | ||
| Genetic pathways to primary and secondary glioblastoma | Q35757144 | ||
| Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model | Q35800497 | ||
| Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer | Q35876172 | ||
| The effect of mouse strain on herpes simplex virus type 1 (HSV-1) infection of the central nervous system (CNS) | Q35968286 | ||
| Differential impact of interferon regulatory factor 7 in initiation of the type I interferon response in the lymphocytic choriomeningitis virus-infected central nervous system versus the periphery | Q36155597 | ||
| Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases | Q36167296 | ||
| Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. | Q36457107 | ||
| Type I interferon response in the central nervous system | Q36780318 | ||
| Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin | Q36943893 | ||
| Neuroimmunology of central nervous system viral infections: the cells, molecules and mechanisms involved. | Q37037317 | ||
| Patterns of antigenic expression of human glioma cells | Q37430142 | ||
| Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas | Q37452837 | ||
| Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects | Q37512434 | ||
| Cloning and expression of murine immune interferon cDNA | Q37514363 | ||
| Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil | Q37756317 | ||
| Membrane perturbation elicits an IRF3-dependent, interferon-independent antiviral response | Q38631749 | ||
| Myxoma virus: propagation, purification, quantification, and storage | Q39707862 | ||
| Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin | Q39752828 | ||
| Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling | Q39849004 | ||
| Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA. | Q40368455 | ||
| Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. | Q41148859 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncolytic virus | Q1560099 |
| Myxoma virus | Q6949366 | ||
| P304 | page(s) | e65801 | |
| P577 | publication date | 2013-06-06 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon | |
| P478 | volume | 8 |
| Q37269034 | ABCG1 maintains high-grade glioma survival in vitro and in vivo. |
| Q30395978 | Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus. |
| Q35545752 | In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells |
| Q38746434 | N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells |
| Q92618072 | Neurofibromin 1 expression is negatively correlated with malignancy and prognosis of epithelial ovarian cancer |
| Q92633759 | Oncolytic Virotherapy with Myxoma Virus |
| Q34405325 | Oncolytic immunotherapy: where are we clinically? |
| Q37672257 | Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma |
| Q39045958 | The role of the immune system in neurofibromatosis type 1-associated nervous system tumors |
| Q51846287 | Tumor Restrictions to Oncolytic Virus. |
| Q35657822 | Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy |
| Q94032022 | Using the Collaborative Cross to Study the Role of Genetic Diversity in Cancer-Related Phenotypes |
| Q63246502 | Virus-Based Immunotherapy of Glioblastoma |
Search more.